NCT02975336: Phase II Clinical Trial

An NCT02975336: Phase II Clinical Trial is a randomized, double-blind, placebo-controlled dose-ranging Phase II clinical trial to evaluate the safety and efficacy of M2951 in subjects With Systemic Lupus Erythematosus (SLE).

• AKA: A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE).
• Context:
  • It can (typically) have an NCT02975336 Protocol (recorded in a NCT02975336 protocol document).
  • ...
• Counter-Example(s):
  • NCT04368728: Phase 1/2/3 Clinical Trial - RNA Vaccine Candidates (COVID-19) [1].
• See: NCT02975336 Protocol Document.

---

---

References

2022

• https://clinicaltrials.gov/ct2/show/NCT02975336
  • Study Description
    • Brief Summary: M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).
      • Condition or disease Intervention/treatment Phase
    • Systemic Lupus Erythematosus Drug: Placebo Drug: M2951 Phase 2
  • Study Design
    • Study Type : Interventional (Clinical Trial)
    • Actual Enrollment : 469 participants
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Double (Participant, Investigator)
    • Primary Purpose: Treatment
    • Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE.
    • Actual Study Start Date : January 4, 2017
    • Actual Primary Completion Date : November 27, 2019
    • Actual Study Completion Date : March 23, 2020

---